🇺🇸 FDA
Pipeline program

Deutetrabenazine

200069

Phase 3 small_molecule active

Quick answer

Deutetrabenazine for Huntington Disease is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Huntington Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials